Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: Effects of race and sex

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 3, 2012, Pages 483-488

  Marino, S E ^a,b   Birnbaum, A K ^a,b,c   Leppik, I E ^a,b,c   Conway, J M ^b   Musib, L C ^d   Brundage, R C ^b   Ramsay, R E ^e   Pennell, P B ^f   White, J R ^a,c   Gross, C R ^b   Rarick, J O ^b   Mishra, U ^a,b   Cloyd, J C ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MINCEP Epilepsy Care   (United States)

^d GENENTECH INC   (United States)

^e Ochsner Baptist Medical Center   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; EPILEPSY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE;

ADMINISTRATION, ORAL; ADULT; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CARBAMAZEPINE; CHEMISTRY, PHARMACEUTICAL; EPILEPSY; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; SEX FACTORS;

EID: 84863393550     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.251     Document Type: Article

References (38)

1. Patsalos, P.N. & Perucca, E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2, 347-356 (2003). (Pubitemid 38352562)
2. Ramsay, R.E. et al. Carbamazepine metabolism in humans: effect of concurrent anticonvulsant therapy. Ther. Drug Monit. 12, 235-241 (1990). (Pubitemid 20150887)
3. Levy, R.H., Lockard, J.S., Green, J.R., Friel, P. & Martis, L. Pharmacokinetics of carbamazepine in monkeys following intravenous and oral administration. J. Pharm. Sci. 64, 302-307 (1975).
4. Eichelbaum, M., Ekbom, K., Bertilsson, L., Ringberger, V.A. & Rane, A. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur. J. Clin. Pharmacol. 8, 337-341 (1975).
5. Rawlins, M.D., Collste, P., Bertilsson, L. & Palm, L. Distribution and elimination kinetics of carbamazepine in man. Eur. J. Clin. Pharmacol. 8, 91-96 (1975).
6. Gadin, A.P., Abadie, F.V., Campestrini, J.A. & Theobald, W. Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses. J. Pharmacokinet. Biopharm. 4, 521-535 (1976). (Pubitemid 8132216)
7. Pitlick, W.H. & Levy, R.H. Time-dependent kinetics I: Exponential autoinduction of carbamazepine in monkeys. J. Pharm. Sci. 66, 647-649 (1977). (Pubitemid 8091921)
8. Bertilsson, L., H?er, B., Tybring, G., Osterloh, J. & Rane, A. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin. Pharmacol. Ther. 27, 83-88 (1980). (Pubitemid 10096585)
9. Tomson, T., Almkvist, O., Nilsson, B.Y., Svensson, J.O. & Bertilsson, L. Carbamazepine-10,11-epoxide in epilepsy. A pilot study. Arch. Neurol. 47, 888-892 (1990).
10. Faigle, J. & Feldmann, K. Pharmacokinetic data of carbamazepine and its major metabolites in man. In: Clinical Pharmacology of Anti-Epileptic Drugs (eds. Schneider, H., Janz, D., Gardner-Thorpe, C., Meinhardi, H. & Sherwin, A.L.159-165 (Springer, Berlin, Germany, 1975).
11. Bourgeois, B.F. & Wad, N. Carbamazepine-10,11-diol steady-state serum levels and renal excretion during carbamazepine therapy in adults and children. Ther. Drug Monit. 6, 259-265 (1984). (Pubitemid 14037114)
12. Albright, P.S. & Bruni, J. Effects of carbamazepine and its epoxide metabolite on amygdala-kindled seizures in rats. Neurology 34, 1383-1386 (1984). (Pubitemid 14047257)
13. Kerr, B.M. et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem. Pharmacol. 47, 1969-1979 (1994).
14. Hata, M. et al. An epoxidation mechanism of carbamazepine by CYP3A4. Bioorg. Med. Chem. 16, 5134-5148 (2008). (Pubitemid 351625878)
15. Huang, W. et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab. Dispos. 32, 1434-1445 (2004). (Pubitemid 39564564)
16. Patsalos, P.N., Stephenson, T.J., Krishna, S., Elyas, A.A., Lascelles, P.T. & Wiles, C.M. Side-effects induced by carbamazepine-10,11-epoxide. Lancet 2, 1432 (1985). (Pubitemid 16138589)
17. Baillie, T.A. The use of stable isotopes in pharmacological research. Pharmacol. Rev. 33, 81-132 (1981).
18. Browne, T.R. et al. Studies with stable isotopes III: pharmacokinetics of tracer doses of drug. J. Clin. Pharmacol. 25, 59-63 (1985). (Pubitemid 15156066)
19. Browne, T.R. Stable isotopes in pharmacology studies: present and future. J. Clin. Pharmacol. 26, 485-489 (1986). (Pubitemid 16095938)
20. Browne, T.R. Stable isotopes in clinical pharmacokinetic investigations. Advantages and disadvantages. Clin. Pharmacokinet. 18, 423-433 (1990). (Pubitemid 20183886)
21. A hn, J.E. et al. Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy. Neurology 71, 38-43 (2008).
22. Loiseau, P. Clinical efficacy and use in epilepsy. In: Antiepileptic Drugs 5th edn. (eds. Levy, R.H., Mattson, R.H. Meldrum, B.S., & Perucca, E.) 262-272 (Lippincott Williams & Wilkins, Philadelphia, PA, 2002).
23. Greenblatt, D.J. & von Moltke, L.L. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J. Clin. Pharmacol. 48, 1350-1355 (2008).
24. Diczfalusy, U. et al. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet. Genomics 18, 201-208 (2008). (Pubitemid 351323234)
25. Harris, R.Z., Benet, L.Z. & Schwartz, J.B. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50, 222-239 (1995).
26. Zhu, B. et al. The distribution and gender difference of CYP3A activity in Chinese subjects. Br. J. Clin. Pharmacol. 55, 264-269 (2003). (Pubitemid 36390756)
27. Schwartz, J.B. The influence of sex on pharmacokinetics. Clin. Pharmacokinet. 42, 107-121 (2003). (Pubitemid 36188552)
28. Meibohm, B., Beierle, I. & Derendorf, H. How important are gender differences in pharmacokinetics? Clin. Pharmacokinet. 41, 329-342 (2002). (Pubitemid 34713088)
29. Svinarov, D.A. & Pippenger, C.E. Relationships between carbamazepinediol, carbamazepine-epoxide, and carbamazepine total and free steadystate concentrations in epileptic patients: the influence of age, sex, and comedication. Ther. Drug Monit. 18, 660-665 (1996). (Pubitemid 26404570)
30. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001). (Pubitemid 32268418)
31. Mesdjian, E. et al. Metabolism of carbamazepine by CYP3A6: a model for in vitro drug interactions studies. Life Sci. 64, 827-835 (1999). (Pubitemid 29100050)
32. Lamba, J.K. et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12, 121-132 (2002). (Pubitemid 34298916)
33. Roy, J.N. et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab. Dispos. 33, 884-887 (2005).
34. Thummel, K.E. & Wilkinson, G.R. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38, 389-430 (1998). (Pubitemid 28231501)
35. Eichelbaum, M., Khe, K.W., Hoffmann, F. & von Unruh, G.E. Use of stable labelled carbamazepine to study its kinetics during chronic carbamazepine treatment. Eur. J. Clin. Pharmacol. 23, 241-244 (1982). (Pubitemid 12028461)
36. Walzer, M.et al. Pharmacokinetics of oral and intravenous carbamazepine in adult patients with epilepsy. Epilepsia 49, 460 (2008).
37. Leppik, I.E., Conway, J.M., Strege, M.A. & Birnbaum, A.K. Intra-individual variability of carbamazepine and valproic acid serum concentrations in elderly nursing home residents. Neurology 74, A121-A122 (2010).
38. C onway, J.M. et al. Safety of an IV formulation of carbamazepine. Epilepsy Res. 84, 242-244 (2009).